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Abstract
Alterations in the gene expression profile in epithelial cells during breast ductal carcinoma (DC) progression have been
shown to occur mainly between pure ductal carcinoma in situ (DCIS) to the in situ component of a lesion with coexisting
invasive ductal carcinoma (DCIS-IDC) implying that the molecular program for invasion is already established in the
preinvasive lesion. For assessing early molecular alterations in epithelial cells that trigger tumorigenesis and testing them
as prognostic markers for breast ductal carcinoma progression, we analyzed, by reverse transcription–quantitative poly-
merase chain reaction, eight genes previously identified as differentially expressed between epithelial tumor cells pop-
ulations captured from preinvasive lesions with distinct malignant potential, pure DCIS and the in situ component of
DCIS-IDC. ANAPC13 and CLTCL1 down-regulation revealed to be early events of DC progression that anticipated the
invasiveness manifestation. Further down-regulation of ANAPC13 also occurred after invasion appearance and the pres-
ence of the protein in invasive tumor samples was associated with higher rates of overall and disease-free survival in
breast cancer patients. Furthermore, tumors with low levels of ANAPC13 displayed increased copy number alterations,
with significant gains at 1q (1q23.1-1q32.1), 8q, and 17q (17q24.2), regions that display common imbalances in breast
tumors, suggesting that down-regulation of ANAPC13 contributes to genomic instability in this disease.
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Introduction
Breast carcinoma is a complex disease that displays molecular hetero-
geneity at both the preinvasive [1–4] and invasive [5,6] stages. Gene
expression pattern is mainly influenced by the expression of hormonal
receptors, estrogen (ER) and progesterone (PR) and ERBB2 onco-
gene, and tumor classification based on expression profile leads to sig-
nificant repercussion on prognosis [5,6].
Ductal carcinoma (DC) of the breast represents 80% of all breast tu-
mors [7] and can be manifested as in situ (DCIS) or as invasive carcinoma
(IDC), the latter of which can be present with or without an in situ com-
ponent (DCIS-IDC). DCIS is characterized by the confinement of cells
within ducts, maintenance of the basal membrane and lack of stromal
invasion. IDC is characterized by the spreading of cancer cells through
ducts by crossing the basal membrane, leading to stromal invasion.
DCIS is thought to be a precursor of IDC [8,9], and its progression
is not predictable using the currently available resources. Conventional
histologic features and biomarkers are not effective for classifying pure
DCIS lesions regarding their ability to invade surrounding tissues and,
consequently, trigger disease progression.
Cell-based studies have reported negligible differences in gene
expression patterns between epithelial cells from IDC and those from
the in situ component of DCIS-IDC lesions [10–12], suggesting that
genetic and molecular abnormalities, important for the acquisition of
invasiveness, are already present in preinvasive epithelial cells [10,13–
15]. In addition, surrounding myoepithelial cells [16–18] and fibro-
blast cells [17,19] certainly play a fundamental role in invasion process.
We have previously shown that most of the divergences in gene
expression patterns during the course of breast tumor progression
occur between epithelial cells from pure DCIS and those from the
in situ component of DCIS-IDC lesions [10]. Therefore, the assess-
ment of the molecular divergence of epithelial tumor cells of same
morphology but with completely different malignant potentials may
uncover key molecular events involved in early steps of DC progression.
In this sense, the goal of this study was to investigate the earliest
molecular alterations important for acquiring invasive capability and
to discover prognostic factors for DC of the breast. Thus, we assessed, by
reverse transcription–quantitative polymerase chain reaction (RT-qPCR),
the expression of eight candidate genes chosen from our previously
published gene expression signature [10], in laser-capture micro-
dissected epithelial tumor cells from pure DCIS and from the in situ
component of DCIS-IDC lesions. The criterion of gene selection
was based on the availability of commercial antibodies for a posterior
immunohistochemistry (IHC) analysis. Protein expression was eval-
uated in a panel of pure DCIS, in situ component of DCIS-IDC
and IDC lesions. ANAPC13 and CLTCL1were showed to be implicated
in the earliest steps of malignant process of tumor cells. ANAPC13
(anaphase-promoting complex subunit 13) encodes a 74-amino acid
protein [20] that participates in the anaphase-promoting complex
(APC/C), a large ubiquitin ligase that controls cell cycle progression
[21], and it is essential at the metaphase-to-anaphase transition.
CLTCL1 (clathrin, heavy chain-like 1) belongs to the clathrin family
and encodes a protein of 1640 amino acids that is highly expressed
in muscle tissues [22,23]. Clathrins are essential for intracellular traffic
[24,25] and participate in the stabilization of mitotic spindle fibers
[26]. The results demonstrated that decreases in ANAPC13 and
CLTCL1 expression occur before DCIS cells manifest morphologic
aspects of invasion. Furthermore, decrease in ANAPC13 expression
seems to be also involved in late stages of tumor progression and in
increasing genomic instability. Moreover, the presence of ANAPC13
protein was associated with higher rates of overall survival and disease-free
survival in general IDC. Together, these results suggest ANAPC13 as a
promising novel molecular prognostic markers for DC.
Materials and Methods
Samples
Frozen samples from five pure DCIS, 15 in situ component of
DCIS-IDC and 10 IDC lesions were used for laser microdissection
and RT-qPCR (Table 1). An independent set of 42 frozen specimens
from IDC lesions was also used. These samples were manually dissected
for enrichment of at least 70% of tumor cells. DNA from the same
42 samples was used for mutation screening and from 33 of these 42
was used for array comparative genomic hybridization (aCGH). Total
RNA from the 33 samples was used for RT-qPCR. For IHC, an
independent set of formalin-fixed paraffin-embedded (FFPE) tumor
breast tissues were organized in two tissue microarrays as described
[27] (Table W1). TMA1 was composed of 41 pure DCIS and 36
in situ component of DCIS-IDC samples, and TMA2 consisted of
187 IDC samples.
For pure DCIS lesions, all slides from each patient were examined
by pathologists to ensure the absence of any previously undetected
microinvasion. The classification of DCIS samples is in accordance
with the World Health Organization guidelines, and the Nottingham
(Elston-Ellis) modification of the Scarff-Bloom-Richardson grade
system (SBR grade) was applied for IDC samples.
All breast cancer samples were previously analyzed by IHC for the
expression of ER (rabbit monoclonal anti-ER, clone SP1; Dako,
Carpinteria, CA), PR (mouse monoclonal anti-PR, clone PgR636;
Dako), and human epidermal growth factor receptor type 2
(HER2) (rabbit polyclonal anti-HER2, 1:1000; Dako). ER, PR,
and HER2 were evaluated according to the recommendations of the
American Society of Clinical Oncology and the College of American
Pathologists guidelines [28,29]. HER2 amplification was assessed in
positive 2+ IDC samples by fluorescence in situ hybridization (FISH)
analysis, following the manufacturer’s standard methods (Dako), and
hybridization was performed with HER2/CEN-17 probes (Dako).
Results were interpreted using the algorithm established by the Amer-
ican Society of Clinical Oncology and College of American Pathologists
guidelines [29]. IDC samples were classified as luminal A (ER+ and/or
PR+, HER2−), luminal B (ER+ and/or PR+, HER2+), HER2+ (ER−, PR−,
HER2+), basal-like [ER−, PR−, HER2−, cytokeratin (CK) 5/6+ and/or
epidermal growth factor receptor (EGFR+)], or unclassified (negative
for all five markers) according to Perou et al. [5] and Khramtosv et al.
[30]. The inclusion criteria were female patients with ductal carcinoma
without preoperative systemic treatment. Samples were obtained from
the tumor bank and the archives of the Department of Investigative
Pathology, A.C. Camargo Hospital Tumor Bank, São Paulo, Brazil.
This study was approved by the Ethics Committee of the Medical
and Research Center of A. C. Camargo Hospital (1143/08).
RNA/DNA Extraction and RNA Amplification
Approximately 4000 cells were laser captured from frozen tissues of
specific component of each breast ductal lesion with PixCell II LCM
system (Arcturus Engineering, Mountain View, CA). RNA isolation
and amplification were performed as described by Castro et al. [10].
RNA isolation of manually dissected frozen tissues was performed
using RNeasy Mini Kit (Qiagen, Germantown, MD). DNA was
isolated by incubating in 600 μl of digestion buffer (25 mM EDTA,
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pH 8.0, 0.25% of sodium dodecyl sulfate, 100mMNaCl, 100mMTris-
HCl, pH 8.0 and 300 μg of proteinase K) at 55°C overnight, followed
by 100% ethanol precipitation, and 70% ethanol washes, and DNA
was recovered in Tris-EDTA, pH 8.0.
RT-qPCR
Complementary DNA converted from 1 μg of amplified RNA
(aRNA) or total RNA, purified from laser-capture microdissected
cells or manually dissected IDC tissues, respectively, was used as
template for RT-qPCR analysis. RT-qPCRs were performed using
the ABI Prism 7900HT Fast Real-time Sequence Detection System
(Applied Biosystems, Foster City, CA). Reactions were carried out in
duplicates using SYBR Green PCR MasterMix (Applied Biosystems)
in a total volume of 20 μl. Dissociation curves were analyzed for each
primer pair to verify the specificity of the RT-qPCR reaction. Only
samples with differences ≤0.6 in quantification cycle (Cq) between
duplicates were considered for the analysis. Five endogenous control
genes, ACTB, BCR, GAPDH, HPRT1, and RPLP0 were evaluated.
The two most stable endogenous genes (HPRT1 and RPLP0) were
selected by using geNorm [31]. Relative gene expression quantification
was calculated using the efficiency-corrected equation [32]. The list of
primers used is shown in Table W2.
Immunohistochemistry
IHC was performed as previously described [27]. Slides were
incubated with the following primary antibodies: mouse monoclonal
anti-ADFP (clone aa5-27, 1:50, Life Span Biosciences, Seattle, WA),
rabbit polyclonal anti-ANAPC13 (1:30; Sigma Aldrich, St. Louis,
MO), goat polyclonal ARHGAP19 (1:50; Santa Cruz Biotechnology,
Santa Cruz, CA), and mouse monoclonal anti-CLTCL1 (clone
2Q2166, 1:300; Abcam, Cambridge, MA) for 2 hours. Samples
stained without the primary antibody were used as negative controls.
Normal breast tissues, known to express these proteins, according to
the Human Protein Atlas were used as positive controls. Samples were
analyzed microscopically (Axioskop 40; Carl Zeiss Co, Tokyo, Japan)
by a pathologist. Nuclear and cytoplasmic staining patterns were con-
sidered in the analysis when detected in at least 10% of the cells.
Nuclear staining was classified using the Allred score (scores 0-8)
[33]. Samples were categorized as negative (scores 0-3) or positive
(scores 4-8). Cytoplasmic staining was considered as absent, weak,
moderate, and strong staining. For determining the correspondence
between messenger RNA (mRNA) and protein, samples were catego-
rized as negative (absent and weak) or positive (moderate and strong).
ANAPC13 and CLTCL1 Antibody Specificity
For both proteins, ANAPC13 and CLTCL1, Western blot assays
were performed for assessing antibodies specificity as described [34].
Proteins were detected using rabbit polyclonal anti-ANAPC13
(1:500; Sigma Aldrich) and mouse monoclonal anti-CLTCL1 (clone
2Q2166, 1:150; Abcam) antibodies. Signals were detected using ECL
horseradish peroxidase–conjugated immunoglobulin G whole anti-
bodies (1:1500; GE Healthcare, Little Chalfont, United Kingdom).
Proteins from MCF7 (HTB-22) and SK-BR-3 (HTB-30) human
breast cancer cell lines (American Type Culture Collection, ATCC,
Manassas, VA) were used. Cell lines were propagated following
ATCC recommendations.
Table 1. Characteristics of Patients and Tumors Selected for RT-qPCR Analysis.
Sample Type Sample Name Clinical Stage Age at Diagnosis (Years) pTNM Nuclear Grade SBR Grade ER Status PR Status P53 Status HER2 Immunostaining
Pure DCIS 1 0 37 Tis N0 M0 ND − − − + ND
2 0 44 Tis N0 M0 2 and 3 − + + − 0
3 0 43 Tis N0 M0 3 − + + − (3+)
4 0 52 Tis N0 M0 3 − + + − (3+)
5 0 58 Tis N0 M0 3 − − − − (3+)
DCIS-IDC* 6 IIa 48 T2 N0 M0 3 II + + + (1+)
7 IIa 75 T2 N0 M0 2 II + + + (2+)
8 IIa 34 T1c N0 M0 3 II + + + (3+)
9 I 55 T1 N0 M0 3 ND − − + (3+)
10 IIIb 44 T4b N1 M0 2 III + + ND (2+)
11 IIb/IIa 57 T2 N2 M0 2 II + + ND (2+)
12 IIb 43 T2 N0 M0 2 II − − + (3+)
13 IIa 48 T2 N0 M0 2 II + + − (2+)
14 I 73 T3 N0 M0 2 II + + − (2+)
15 ND 46 T2 N1 M0 3 II + + + (2+)
16 IIa 48 T2 N1 M0 3 II − − − (2+)
17 ND 63 T2 N0 M0 1 ND + − − (2+)
18 ND 39 T1c N0 M0 ND ND + + ND (3+)
19 ND 49 T1c N0 M0 ND ND + + ND (0)
20 IIb 69 T2 N1 M0 ND ND + + ND (2+)
IDC 21 IIa 45 T2 N0 M0 2 II − − − (3+)
22 IIa 43 T1c N0 M0 3 II + − − (3+)
23 IIa 54 T2 N0 M0 3 II + + + (3+)
24 IIIb 71 T4 N2 M0 3 III + + + (2+)
25 IIa 43 T2 N0 M0 3 III − ND ND (3+)
26 IIIa 43 T2 N2 M0 3 III + + ND (2+)
27 I ND ND ND ND ND ND ND ND
28 IIa 44 T1 N1 M0 3 II + + − (1+)
29 IIb 31 T2 N1 M0 3 II − − + (3+)
30 IIIa 54 T3 N1 M0 3 III − − − (2+) (1+)
DCIS indicates ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with coexisting invasive ductal carcinoma; ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2;
ND, not determined; PR, progesterone receptor; pTNM, pathologic tumor size, nodal status, and metastasis.
*DCIS-IDC samples were classified according to the IDC lesion.
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ANAPC13 Mutation Screening
Primers corresponding to all exonic regions and also the exon/
intron borders of ANAPC13 were designed (Table W2). ANAPC13
mutation screening was performed for the 42 frozen IDC samples.
PCR products were confirmed by agarose gel electrophoresis and se-
quenced using the 3130XL Genetic Analyzer (Applied Biosystems,
Foster City, CA). For all samples, sequences were obtained using both
forward and reverse primers and analyzed in CLC DNA Genomics
Workbench software 4.5 (CLCbio, Katrinebjerg, Denmark), using
RefSeq NM_015391.3 as reference.
Investigation of Copy Number Alterations by Whole Genome
Comparative Genomic Hybridization on Microarrays
Array CGH (aCGH) investigation was performed on 33 of the
42 frozen IDC samples by oligonucleotide array CGH using whole-
genome platforms from Agilent Technologies (Agilent SurePrint G3
Human CGHMicroarrays 8×60K [containing 60,000 oligonucleotides
probes] and 4×180K [containing 180,000 oligonucleotides probes]).
Briefly, samples were labeled with Cy3- and Cy5-dCTPs by random
priming, and purification, hybridization, and washing were carried
out as recommended by the manufacturer. Scanned images of the arrays
were processed using Feature Extraction software (Agilent Technologies,
Santa Clara, CA), and the analysis was carried out using Nexus Copy
Number 5.1 (Biodiscovery, El Segundo, CA). For aCGH analysis,
identification of aberrant copy number segments was based on FASST2
segmentation algorithm with default settings (threshold log2 ratio of
0.2 or 1.14 was used for gain or high copy gain, and −0.23 and −1.14
used for loss and homozygous loss, respectively), and the significance
threshold was set on 1.0−7. We considered at least three consecutive
probes for calling a segment, and a filter against aberrations smaller than
150 kb was used.
Statistical Analysis
For RT-qPCR analyses, a criterion of fold change ≥ |2| was applied
for considering differentially expressed genes. The IHC statistical anal-
yses were performed with STATA software (Intercooled Stata release
7.0; Stata Corporation, College Station, TX). For the categorical vari-
ables, the χ2 or Fisher exact test was applied. Overall survival and
disease-free survival probabilities were calculated using the Kaplan-
Meier method, and the log-rank test was used to compare survival
curves. The Cox regression model was used to estimate relative risks
with a confidence interval of 95% and to obtain independent prognostic
variables. Results were considered statistically significant when P < .05.
Results
Assessment of Gene Expression in Tumor Epithelial Cells from
Pure DCIS and the In Situ Component of DCIS-IDC
To identify novel molecular markers for the progression of DC of the
breast, we explored differences in gene expression that occur in epithe-
lial cells from preinvasive lesions, pure DCIS, and the in situ compo-
nent of DCIS-IDC. Epithelial tumor cells were captured by laser from
five pure DCIS and from 15 in situ component of DCIS-IDC samples
(Figure 1A and Table 1). Eight genes (ADFP, ANAPC13, ARHGAP19,
CLTCL1, CPNE3, IMMT,NGDN, and PIAS2) selected from our pre-
vious study [10], were assessed by RT-qPCR in both cell populations,
pure DCIS, and the in situ component of DCIS-IDC. For this analysis,
complementary DNA was converted from amplified RNA and used
for RT-qPCR experiments because no introduction of bias in relative
gene expression was previously detected [35]. Four genes showed con-
cordant results between RT-qPCR and microarray data [10], ADFP
(RT-qPCR fold change = 2.79), ANAPC13 (RT-qPCR fold change =
2.00), ARHGAP19 (RT-qPCR fold change = 6.88), and CLTCL1
Figure 1. mRNA down-regulation of ANAPC13 and CLTCL1 along the progression of epithelial tumor cells of the breast. (A) Breast
epithelial cells captured from pure DCIS, in situ component of DCIS-IDC and IDC lesions by laser-capture microdissection. Original mag-
nifications, ×100. (B) Relative mRNA expression of ANAPC13 and CLTCL1 in pure DCIS, in situ component of DCIS-IDC and IDC. DCIS
indicates ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with coexisting invasive ductal carcinoma; IDC, invasive ductal
carcinoma. *P < .05.
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(RT-qPCR fold change = 6.25) displaying up-regulation in pure DCIS
cells. The remaining four genes did not fullfill the adopted criterion dif-
ferences in expression levels between epithelial cells from pure DCIS and
those from the in situ component of DCIS-IDC.
Assessment of Protein Expression in Pure DCIS and
in the In Situ Component of DCIS-IDC
To assess protein expression, samples from 41 pure DCIS lesions
and 36 in situ component of DCIS-IDC lesions (TMA1) were stained
with antibodies against ADFP, ANAPC13, ARHGAP19, and
CLTCL1 and evaluated by IHC. ADPF and CLTCL1 showed cyto-
plasmic staining, whereas ANAPC13 and ARHGAP19 showed both
nuclear and cytoplasmic staining. Samples were categorized as negative
(absent or weak staining) or positive (moderate or strong staining).
Results of cytoplasmic staining for ANAPC13 and CLTCL1 were con-
cordant with those observed at the mRNA level (Figure 1B). Positive
ANAPC13 was detected in 69.5% of pure DCIS samples and in
40.8% of in situ component of DCIS-IDC samples (P = .02). Positive
CLTCL1 was detected in 60.0% of pure DCIS samples and in 35.5%
of in situ component of DCIS-IDC samples (P = .04; Table 2). In
contrast, no statistically significant differences were found in cyto-
plasmic staining for ADFP and ARHGAP19 and nuclear staining for
ANAPC13 and ARHGAP19 between pure DCIS and in situ com-
ponent of DCIS-IDC samples (Table W3). Assessment of associations
between immunostaining patterns and clinicopathologic variables
(Table 2) demonstrated statistically significant associations between
positive cytoplasmic ANAPC13 samples and positive status for ER
and PR (P < .01).
To better characterize the protein sublocation of ANAPC13 and
CLTCL1, we firstly assessed the antibodies specificity (Figure 2) and
then evaluated 10 entire lesions (5 pure DCIS and 5 in situ com-
ponent of DCIS-IDC lesions) using ScanScope XT scanner (Aperio,
Vista, CA). Sharp patterns of nuclear and/or cytoplasmic staining were
observed for ANAPC13. For CLTCL1, staining was mainly cytoplasmic
with some membrane staining. No nonspecific stromal or parenchymal
staining was observed for either antibody (Figure 2).
Assessment of the Transcriptional Levels of ANAPC13
and CLTCL1 during Tumor Progression
To assess modulation of ANAPC13 and CLTCL1 mRNA levels
during the progression of tumor epithelial cells in DC, we evaluated
epithelial cells captured from 10 invasive ductal carcinoma samples
(IDC) by RT-qPCR. ANAPC13 mRNA levels progressively de-
creased in epithelial cells from IDC when compared with cells from
the in situ component of DCIS-IDC lesions (fold change = 2.78; P =
.02) (Figure 1B). No difference was observed in CLTCL1 expression
between cells from the in situ component of DCIS-IDC and IDC
cells (fold change = 1.00; P = .88) (Figure 1B).
Protein Expression of ANAPC13 and CLTCL1 during
Tumor Progression
To investigate the protein levels of ANAPC13 and CLTCL1 during
DC progression, cytoplasmic expression of both proteins was evaluated
in a second TMA (TMA2) composed of 187 IDC tissues. Absent stain-
ing was observed in 39.0% of the IDC samples, whereas weak or mod-
erate staining was detected in 40.1% and 20.9% of the cases, respectively.
Strong cytoplasmic staining for ANAPC13 was not observed in IDC
samples. Absent staining for CLTCL1 was observed in 25.2% of the
samples, whereas weak, moderate, and strong staining were detected in
43.6%, 26.2%, and 5.0% of the IDC cases, respectively.
To confirm whether the mRNA and protein expression levels were
in agreement during breast cancer progression, we assessed the fre-
quency of samples categorized in IHC as negative (absent and weak
staining) and as positive (moderate and strong staining) (Figure 3A)
in each sample group (pure DCIS, in situ component of DCIS-IDC
and IDC). Both proteins showed tendencies, similar to those observed
at the mRNA level. The frequency of samples classified as positive for
ANAPC13 protein was clearly reduced in IDC lesions. The opposite
was observed for the samples classified as negative for ANAPC13
(Figure 3B). The frequency of positive samples for CLTCL1 was re-
duced in the in situ component of DCIS-IDC when compared with
pure DCIS lesions; however, similar frequencies of CLTCL1-positive
samples were observed between lesions representative of the in situ
component of DCIS-IDC and of IDC (Figure 3B). Together, these
Table 2. ANAPC13 and CLTCL1 Expression (Cytoplasmic Staining) in a Tissue Microarray Composed of In Situ Lesions.
Variable Category ANAPC13, n (%)* P CLTCL1, n (%)* P
Negative Positive Negative Positive
Histologic type of DCIS Pure DCIS 11 (30.50) 25 (69.50) .02† 14 (40.00) 21 (60.00) .04†
In situ component of DCIS-IDC 16 (59.20) 11 (40.80) 20 (64.50) 11 (35.50)
Histologic subtype Non-comedo 21 (41.20) 30 (58.80) .42 29 (54.70) 24 (45.30) .09
Comedo 6 (54.60) 5 (45.40) 3 (27.30) 8 (72.70)
Nuclear grade Non-high grade 14 (41.20) 20 (58.80) .49 19 (57.60) 14 (42.40) .26
High grade 13 (50.00) 13 (50.00) 13 (43.30) 17 (56.70)
Histologic grade Non-high grade 12 (38.70) 19 (61.30) .32 18 (60.00) 12 (40.00) .19
High grade 13 (52.00) 12 (48.00) 12 (42.90) 16 (57.10)
ER status Negative 12 (75.00) 4 (25.00) <.01‡ 11 (57.90) 8 (42.10) .46
Positive 12 (30.80) 27 (69.20) 19 (47.50) 21 (52.50)
PR status Negative 18 (62.10) 11 (37.90) <.01‡ 16 (50.00) 16 (50.00) .88
Positive 6 (23.10) 20 (76.90) 13 (48.20) 14 (51.80)
HER2 status Negative 4 (57.00) 3 (43.00) .68 5 (63.00) 3 (38.00) .46
Positive 21 (44.00) 27 (56.00) 22 (47.00) 25 (53.00)
DCIS indicates ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with coexisting invasive ductal carcinoma; ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2;
PR, progesterone receptor.
*Percentage considering number of cases with complete information.
†P value < 0.05.
‡P value < 0.01.
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Figure 2. Protein expression of ANAPC13 and CLTCL1 in pure DCIS and in the in situ component of DCIS-IDC. Immunohistochemical
staining, showing higher expression of ANAPC13 and CLTCL1 proteins in lesions representative of pure DCIS (left) and in situ compo-
nent of DCIS-IDC (right). Level of background or nonspecific staining, sharpness, intensity, and localization were considered in the IHC
analysis. Antibody specificity determined by Western blot for ANAPC13 (19 kDa) and for CLTCL1 (192 kDa) (right panel). Images acquired
from ScanScope XT scanner (Aperio). Original magnifications, ×200. DCIS indicates ductal carcinoma in situ; DCIS-IDC, ductal carcinoma
in situ with coexisting invasive ductal carcinoma; MCF7 and SKBR-3, human breast cancer cell lines.
Figure 3. Frequencyof positive andnegativeprotein staining of ANAPC13andCLTCL1 alongDCprogression. (A) Immunohistochemical analy-
sis of ANAPC13 and CLTCL1, showing examples of the immunostaining pattern categorized as negative (absent and weak staining) and
positive (moderate and strong staining). For ANAPC13, strong staining was only observed in DCIS lesions. Images acquired from ScanScope
XT scanner (Aperio). (B) Graphbars representing the frequency of positive and negative protein stainingof ANAPC13 andCLTCL1 in pure DCIS,
in situ component of DCIS-IDC, and IDC lesions, respectively. DC indicates ductal carcinoma; DCIS, ductal carcinoma in situ; DCIS-IDC, ductal
carcinoma in situ with coexisting invasive ductal carcinoma; IDC, invasive ductal carcinoma. *P < .05, **P < .01, ***P < .001.
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results suggest that the down-regulation of ANAPC13 may be in-
volved not only in early molecular alterations that precede the mor-
phologic manifestation of invasion but also in late stages in the
progression of epithelial cells of DC, whereas, down-regulation of
CLTCL1 seems to be an early event that anticipates the invasive pheno-
type and that occurs at a defined time during DC progression.
ANAPC13 and CLTCL1 as Prognostic Factors for Invasive
Ductal Carcinoma
We next tested the prognostic potential of ANAPC13 and CLTCL1
by analyzing possible associations of these proteins with the clinico-
pathologic variables of the IDC samples. No statistically significant
associations were observed between protein staining patterns and
clinicopathologic variables (Table 3). Next, univariate analysis was per-
formed to assess the association of cytoplasmic staining of ANAPC13
and CLTCL1 with overall and disease-free survival in patients with in-
vasive breast carcinoma (Table W4) categorizing as negative, absent
staining, and positive, weak, moderate, and strong staining. Overall
and disease-free survival rates were higher among patients with positive
cytoplasmic expression of ANAPC13 (log-rank test, P = .003 and P =
.04, respectively; Figure 4, A and B). These results strongly suggest the
potential of ANAPC13 as a favorable prognostic factor in IDC. Accord-
ing to the Cox regression univariate model, patients with negative
ANAPC13 cytoplasmic tumors had a two-fold higher risk of dying than
patients with tumors positive for this protein (crude hazard ratio = 2.00,
95% confidence interval = 1.3-3.2). Multivariate analysis demonstrated
that ANAPC13 is an independent prognostic factor (hazard ratio =
2.09, 95% confidence interval = 1.3-3.4), reinforcing it as a promising
molecular marker for IDC (Table W5).
Finally, we classified the IDC samples based on their molecular sub-
types as luminal A (n = 106), luminal B (n = 12), HER2+ (n = 19),
basal-like (n = 12), and unclassified (n = 19) lesions (Tables W6 and
W7) as defined in Materials and Methods. Only luminal A subtype
showed a significant association between positive ANAPC13 and the
presence of three or less compromised lymph nodes (P = .0158). In
addition, among luminal A samples, the overall survival rate was higher
for patients with positive ANAPC13 samples (log-rank test, P = .004;
Figure 4C). No significant associations were found between ANAPC13
staining categories and disease-free survival in luminal A cases (Figure 4D)
as well as for overall and disease-free survival rates in the other mo-
lecular subtypes.
Mutation Screening in ANAPC13 Gene
Given that ANAPC13 down-regulation seems to play an important
role during DC progression, we evaluated whether protein inter-
ruption causing mutations in ANAPC13 could lead to decreased
expression during late stages of tumor progression. Thus, the three
exons, two of them coding, and the exon/intron borders of ANAPC13
were analyzed by DNA sequencing in 42 IDC samples. Seven altera-
tions were found, but none of them were within the coding sequence
indicating that mutation may not be the event that contributes to the
decrease or absence of ANAPC13 protein in breast tumor (Table W8
and Figure W1A).
Copy Relation of ANAPC13 Expression and Copy
Number Alterations
We reasoned that decrease of ANAPC13 could result in genomic
instability during breast tumor progression. To test this hypothesis, we
classified a group of 33 IDC samples based on their ANAPC13 tran-
scriptional levels by RT-qPCR. Fourteen and 19 samples expressed low
and high levels of ANAPC13, respectively (P < .0001; Figure 5A). Next,
copy number alterations (CNAs) were assessed using genomic DNA
from the same sample set. A statistically significant association between
low levels of ANAPC13 and increased numbers of CNAs was observed
(P = .048; Figure 5B). Breast tumor samples with low expression of
this gene displayed 767 gains and 906 losses, whereas 355 gains and
377 losses were observed in the group of breast samples with high ex-
pression of ANAPC13. In these sample groups, no overrepresentation
of any molecular subtypes was observed (P = .36; Table W9). Interest-
ingly, the increased number of gains in samples expressing low levels
of ANAPC13 was mainly observed in the chromosomal regions where
imbalances in breast tumor samples are frequently detected, such as
gains at 1q (1q23.1-1q32.1), 8q, and 17q (17q24.2) [36] (Figure 5C).
We also used the aCGH data for checking whether the absence
of ANAPC13 protein in IDC samples could be a result of loss of
ANAPC13 chromosomal region. No ANAPC13 losses were detected
suggesting that other mechanisms are involved in the down-regulation
of ANAPC13 in breast tumor (Figure W1B).
Discussion
Ductal breast cancer progression is a multistep process in which con-
tinuous accumulation of molecular abnormalities leads to a series of
histopathologic stages, namely flat epithelial atypia followed by atyp-
ical ductal hyperplasia, DCIS, and IDC, which may lead to metastatic
disease and death [8,9]. In a cell-based microarray experiment, we
observed that most of the molecular alterations in epithelial cells
during breast cancer progression occur between cells of two morpho-
logically similar lesions, pure DCIS and the in situ component of
DCIS-IDC lesions, rather than between the in situ component of
DCIS-IDC and IDC lesions, suggesting that molecular changes occur
before the appearance of morphologic modifications [10]. By identi-
fying changes in gene expression that precede DC invasion, we rea-
soned that is possible to unveil potential markers for clinical
application, especially concerning the risk of progression of both pure
DCIS and early-stage IDC lesions. Therefore, we examined changes
in gene expression between pure DCIS and the in situ component of
DCIS-IDC. We assessed eight genes, for which commercial anti-
bodies are available, permitting the use of FFPE tissues for validation
by IHC. That is especially important for pure DCIS lesions, which
owing to their tiny size, are often entirely used for diagnosis proposals.
This fact has hindered the identification of biomarkers for progression
of pure DCIS, using frozen tissues for RNA-based analysis, consider-
ing the importance of assessing large and independent set of samples
in the validation process. In addition, the low-quality RNA obtained
from FFPE tissues can introduce bias in relative gene expression even
with the improvements in the protocols for isolating RNA from FFPE
tissue for assessing transcriptional data [37,38].
Among the eight genes tested, two, ANAPC13 and CLTCL1, pre-
sented the potential to play an important role in DC progression.
Both demonstrated decreased expression at both the mRNA and
protein levels in the in situ component of DCIS-IDC lesions.
Differences in protein expression levels between the two types of
preinvasive lesions, pure DCIS and the in situ component of DCIS-
IDC, have also been reported by others [39,40]. ER, PR, and EGFR
have been found to be more highly expressed in pure DCIS com-
pared to in situ component of DCIS-IDC [40,41], reinforcing the
existence of molecular differences between tumor cells from these
two lesion types with similar morphology.
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Table 3. ANAPC13 and CLTCL1 Expression (Cytoplasmic Staining) in a Tissue Microarray Composed IDC Samples.
Variable Category ANAPC13, n (%)* P CLTCL1, n (%)* P
Negative Positive Negative Positive
Lymph node metastasis ≤3 34 (32.00) 72 (68.00) .09 30 (28.60) 75 (71.40) .08
>3 23 (46.00) 27 (54.00) 8 (16.00) 42 (84.00)
In situ lesion Absent 40 (50.00) 40 (50.00) .24 19 (24.40) 59 (75.60) .36
Present 10 (37.00) 17 (63.00) 9 (33.30) 18 (67.70)
ER status Negative 24 (40.70) 35 (59.30) .60 14 (23.30) 46 (76.70) .83
Positive 44 (36.70) 76 (63.30) 29 (24.80) 88 (75.20)
PR status Negative 42 (42.90) 56 (57.10) .38 25 (25.00) 75 (75.00) .83
Positive 28 (36.40) 49 (63.60) 17 (23.60) 55 (76.40)
HER2 status Negative 54 (38.00) 88 (62.00) .64 35 (25.00) 103 (75.00) .89
Positive 14 (42.00) 19 (58.00) 8 (24.00) 25 (76.00)
EGFR Negative 53 (38.00) 87 (62.00) .90 32 (23.00) 106 (77.00) .26
Positive 11 (37.00) 19 (63.00) 9 (33.00) 18 (67.00)
CK5/6 Negative 51 (39.00) 79 (61.00) .99 27 (22.00) 98 (78.00) .06
Positive 17 (39.00) 27 (61.00) 16 (36.00) 29 (64.00)
Nuclear grade 1 1 (50.00) 1 (50.00) .96 1 (50.00) 1 (50.00) .77
2 19 (44.20) 24 (55.80) 11 (28.20) 28 (71.80)
3 48 (46.20) 56 (53.80) 28 (27.20) 75 (72.80)
SBR grade 1 13 (44.80) 16 (55.20) .98 9 (33.30) 18 (66.70) .70
2 40 (46.50) 46 (53.50) 24 (28.20) 61 (71.80)
3 15 (46.90) 17 (53.10) 7 (23.30) 23 (76.70)
Clinical stage I + II 34 (44.00) 44 (56.00) .68 26 (30.00) 62 (70.00) .08
III + IV 34 (40.00) 50 (60.00) 15 (18.00) 67 (82.00)
CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2; IDC, invasive ductal carcinoma; PR, progesterone receptor.
*Percentage considering number of cases with complete information.
Figure 4. Kaplan-Meier survival curves based on ANAPC13 cytoplasmic staining. The overall survival time was defined as the interval
between the beginning of treatment (surgery) and the date of death or the last information for censored observations. The disease-free
interval was measured from the date of the treatment to the date when recurrence was diagnosed. The follow-up period varied from 1 to
180 months (73.8 ± 39.8, mean ± SD). A total of 64 recurrences were observed, and the time of these recurrences varied from 1 to
176.2 months (34.5 ± 38.6, mean ± SD). Overall survival (A) and disease-free survival (B) in patients positive or negative to ANAPC13
cytoplasmic staining with invasive ductal carcinoma. Overall survival (C) and disease-free survival (D) in luminal A group positive or
negative to ANAPC13 cytoplasmic staining.
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The fact that CLTCL1 expression decreases at the mRNA and
protein levels in the earliest stages of tumor progression, when the
cells still exhibit a preinvasive phenotype, but shows no further
changes in expression during late stages of tumor progression high-
lights the potential of this gene as a biomarker for risk of progression
of pure preinvasive lesions. Modulation of the expression of clathrins
and/or clathrin adaptors seems to have a role in tumorigenesis and
cell proliferation [42]. Although additional evidence of CLTCL1 im-
portance in the context of DCIS progression is necessary, the current
analysis is the first study, to our knowledge, that associates CLTCL1
with breast tumors.
The expression of ANAPC13 decreased progressively at both the
mRNA and protein levels during the course of tumor progression.Multi-
variate analyses associated positive ANAPC13 categories of breast tumors
with higher rates of survival, suggesting that the presence of ANAPC13
may be a protective factor for patients with DC of the breast.
In overall survival, the protective effect of ANAPC13 expression
was especially clear in luminal A cases, defined as ER- and/or PR-
positive and HER2-negative. Although they are thought to have a
good prognosis, luminal A breast tumors are a heterogeneous group
including patients with distinct clinical outcomes. Therefore, the
importance of novel molecular markers able to stratify tumors for
more efficient and individualized treatment is obvious [43,44], and
ANAPC13 may have an important role in the subclassification of
luminal A cases.
On the basis of the role of ANAPC13, as a subunit of APC/C com-
plex, which is responsible for destroying the cohesion between sister
chromatids by the activation of a protein called cysteine-protease
separase, enabling the mitotic spindle to pull sister chromatids to op-
posite spindle poles [45], we decided to investigate the relation between
ANAPC13 expression and CNAs. A statistically significant associa-
tion was observed between a low expression of ANAPC13 and higher
Figure 5. Correspondence between ANAPC13 expression and genomic instability in invasive ductal carcinoma. (A) Relative mRNA
expression in IDC cases with high and low expression of ANAPC13 by RT-qPCR. (B) Number of CNAs in IDC samples with high and low
expression of ANAPC13. (C) The x axis corresponds to the genomic region from chromosomes 1 to 22, X and Y, and the y axis represents
the percentage of gains (plotted in blue above the 0% baseline) and losses (plotted in red below the 0% baseline) in all selected samples
at the specified location in genome. The upper panel shows genome-wide CNAs (gains and losses) in 33 breast tumors. The middle and
lower panels show frequency plots of breast tumors grouped according to ANAPC13 expression status (high and low expression, respec-
tively). Breast tumors with low ANAPC13 expression show a distinctive pattern of genomic alterations mainly characterized by an increased
frequency of gains at 1q (1q23.1-1q32.1), 8q, and 17q (17q24.2) (represented by black bars). Images obtained from Nexus copy number
5.1 software (Biodiscovery). Chr indicates chromosome; CNAs, copy number alterations. *P < .05, ***P < .001.
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number of CNAs. Triple-negative tumors are more likely to present
genetic instability, and this is especially apparent in the basal-like sub-
type [36]. We did not observe overrepresentation of any of the molecular
subtypes in either the ANAPC13 high- or low-expressing groups,
indicating that down-regulation of ANAPC13 expression is probably
associated to increased chromosomal instability in breast tumors.
ANAPC13 down-regulation does not seem to be a reflection of
truncated proteins generated by non–sense mutation or frameshift
mutation because no alterations in breast tumor DNA were observed
in the coding sequence of this gene. Other mechanisms that regulate
transcriptional expression, such as epigenetic modifications or micro-
RNA, might be involved in the decrease of mRNA and protein
expression levels.
Much attention has been focused on understanding how epithelial
cells can survive in a hypoxic, nutrient-deprived in situ niche and
how that niche in turn promotes genetic instability and triggers an
invasive phenotype by selecting neoplastic cells with invasive capacity
[14,46,47]. Although the current study demonstrates that tumors
expressing low levels of ANAPC13 harbored higher number of CNAs,
the precise role played by ANAPC13 in genomic instability remains to
be addressed. A more thorough investigation of ANAPC13 function
in the context of breast cancer, especially its function in genomic
instability, may contribute to the understanding of mechanisms
underlying the progression of DC.
Together, the results presented in this study strongly suggest that
the investigation of the molecular differences between epithelial tumor
cells from pure DCIS and from the in situ component of DCIS-IDC,
which are representative of the first molecular alterations that precede
morphologic modifications, can result in the identification of novel
molecular markers involved in the progression of ductal carcinoma of
the breast.
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Table W1. Distribution of Breast Cancer Cases According to Clinicopathologic Variables.
Variable Category TMA 1 (Pure DCIS and DCIS-IDC), n (%)* TMA 2 (Invasive Samples), n (%)*
Histologic type of DCIS Pure DCIS 44 (55.00) NA
In situ component of DCIS-IDC 36 (45.00) 27 (14.40)
IDC NA 160 (85.60)
Histologic subtype Non-comedo 62 (82.70) ND
Comedo 13 (17.30) ND
Nuclear grade 1 4 (5.60) 2 (1.30)
2 33 (46.50) 43 (28.30)
3 34 (47.90) 107 (70.40)
Histologic grade Non-high grade 34 (51.5) ND
High grade 32 (48.5) ND
SBR grade 1 ND 29 (19.30)
2 ND 89 (59.30)
3 ND 32 (21.30)
Clinical stage I + II ND 78 (48.00)
III + IV ND 84 (52.00)
Estrogen receptor status Negative 22 (32.80) 61 (33.20)
Positive 45 (67.20) 123 (66.80)
Progesterone status Negative 31 (46.27) 103 (57.20)
Positive 36 (53.73) 77 (42.80)
HER2 status Negative 11 (16.70) 145 (83.30)
Positive 55 (83.30) 29 (16.70)
CK5/6 Negative ND 130 (73.00)
Positive ND 48 (27.00)
EGFR Negative ND 144 (82.80)
Positive ND 30 (17.20)
Recurrence No ND 75 (52.82)
Yes ND 67 (47.18)
Lymph node metastasis ≤3 ND 108 (67.00)
>3 ND 53 (33.00)
Adjuvant chemotherapy No ND 77 (54.2)
Yes ND 65 (45.8)
Radiotherapy No ND 37 (26.0)
Yes ND 105 (74.0)
Hormone therapy No ND 75 (52.8)
Yes ND 67 (47.2)
CK, cytokeratin; DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with coexisting invasive ductal carcinoma; HER2, human epidermal growth factor receptor type 2; IDC, invasive
ductal carcinoma; NA, not applicable; ND, not determined; SBR grade, Scarff-Bloom-Richardson grade; TMA, tissue microarray.
*Percentage considering the number of cases with complete information.
Table W2. Genes and Primer Sequences Used in RT-qPCR and Mutation Screening Analysis.
RT-qPCR Analysis Mutation Analysis
Gene Symbol Annotation Primer Sequences (5′-3′) Primer Sequence Exons Analyzed
ADFP (GenBank: NM_001122.2) Adipose differentiation-related protein Forward: GATACTGATGAGTCCCACTG Forward: CCAGCCTCTGTAGTCGG 1
Reverse: GGTACACCTTGGATGTTGG Reverse: GGGACACGTCTTATCAATTTC
ANAPC13 (GenBank: NM_015391.3) Anaphase-promoting complex
subunit 13
Forward: GATTGATGATGCTTGGCG Forward: GTACGGTGCGGATGGTG 1
Reverse: GTAAGGCTAAGTCTGTCC Reverse: CAGGGCACACTGATTATCTTG
ARHGAP19 (GenBank: NM_032900) Rho GTPase activating protein 19 Forward: CAAGATTGAAGTGGTCTGAAG Forward: GGAGAGAGGAACTGTGATC 2
Reverse: CAAGATTGAAGTGGTCTGAAG Reverse: GTTAGAGAATTCCACAGCTTTG
CLTCL1 (GenBank: NM_01835.3) Clathrin, heavy chain-like 1 Forward: GATGGGCATGAATGAGAC Forward: CCTAGGAACTCACAAGC 3
Reverse: CGAAGTTGGGAGCAGA Reverse: GCCTTTCCCTCTCATA
CPNE3 (GenBank: 003909.3) Copine III Forward: CGAAGTTGGGAGCAGAG Forward: GCTGTCAAAGTTTAACACC 3
Reverse: CTGCCAAGACACACTGAG Reverse: GGATGTATCTGGATTATAGG
IMMT (GenBank: 006839.2) Inner membrane protein,
mitochondrial
Forward: GATCACTTGCGAGATGTCC
Reverse: GACTGAGACGACGAAATTG
NGDN (GenBank: NM_001042635.1) Neuroguidin, EIF4E binding protein Forward: CGTTTTAAGCCTCATCCCAG
Reverse: CATCTTCTGCTTCATCTTCCTC
PIAS2 (GenBank: NM_0046712) Protein inhibitor of activated STAT2 Forward: GACCGAAGAAAGAAGCTATG
Reverse: GTCACTGAACAAGGCTTAC
ACTB (GenBank: MN_001101.3) Actin beta Forward: GCACCCAGCACAATGAAG
Reverse: CTTGCTGATCCACATCTGC
BCR (GenBank: NM_004327) Breakpoint cluster region Forward: CCTTCGACGTCAATAACAAGGAT
Reverse: CCTGCGATGGCGTTCAC
GAPDH (GenBank: AJ00531) Glyceraldehyde-3-phosphate
dehydrogenase
Forward: GAAGGTGAAGGTCGGA
Reverse: GGGTCATTGATGGCAAC
HPRT1 (GenBank: NM_000194.2) Hypoxanthine
phosphoribosyltransferase 1
Forward: CCCACGAAGTGTTGGATATAAGC
Reverse: GGGCATATCCTACAACAAACTTGTC
RPLP0 (GenBank: NM_001002) Hydrogenase expression/formation Forward: GGAGACGGATTACACCTTC
Reverse: CTTCAACCTTAGCTGGGG
Table W3. ADFP, ANAPC13, ARHGAP19 and CLTCL1 Expression in a Tissue Microarray Composed of In Situ Lesions.
Protein IHC Analysis Histologic Type of DCIS P
Pure DCIS In Situ Component of DCIS-IDC
ADFP (cytoplasmic staining) (%)* Negative 26 (68.40) 22 (73.30) .28
Positive 12 (31.60) 8 (26.70)
ANAPC13 (nuclear staining) (%)* Negative 13 (35.10) 10 (38.40) .78
Positive 24 (64.90) 16 (61.60)
ANAPC13 (cytoplasmic staining) (%)* Negative 11 (30.50) 16 (59.20) .02†
Positive 25 (69.50) 11 (40.80)
ARHGAP19 (nuclear staining) (%)* Negative 25 (71.40) 14 (50.00) .08
Positive 10 (28.60) 14 (50.00)
ARHGAP19 (cytoplasmic staining) (%)* Negative 11 (31.40) 8 (28.60) .80
Positive 24 (68.60) 20 (71.40)
CLTCL1 (cytoplasmic staining) (%)* Negative 14 (40.00) 20 (64.50) .04†
Positive 21 (60.00) 11 (35.50)
DCIS indicates ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with coexisting invasive ductal carcinoma.
*Percentage considering the number of cases with complete information.
†P < .05.
Table W4. Association between Overall and Disease-Free Survival with ANAPC13 Cyto-
plasmic Expression.
Variable Category ANAPC13 (%)
Negative Positive
Overall survival 5 years 50.4 73.0
10 years 34.9 55.9
15 years 21.4 33.8
Disease-free survival 5 years 51.8 63.2
10 years 40.4 61.7
15 years 31.4 50.8
Table W5. Independent Prognostic Factors According to the Cox Regression Model.
Variable Category Crude HR (95% IC)* HR (95% IC)* Multivariate Analysis
SBR grade 1 1.0 1.0
2 2.58 (1.2-5.3) 2.42 (1.1-5.2)
3 3.60 (1.6-8.0) 4.29 (1.8-10.1)
T stage T1 + T2 1.0 1.0
T3 + T4 2.50 (1.5-4.1) 2.26 (1.3-3.9)
M stage 0 1.0 1.0
1 5.77 (3.2-10.2) 4.11 (2.2-7.7)
ANAPC13 (cytoplasmic staining) Positive 1.0 1.0
Negative 2.00 (1.3-3.2) 2.09 (1.3-3.4)
HR indicates hazard ratio; M, metastasis; SBR grade, Scarff-Bloom-Richardson grade; T, tumor.
*Risks for death and 95% confidence interval.
Table W6. Association between ANAPC13 Cytoplasmic Staining and Clinicopathologic Variables in IDC Cases Classified According to the Molecular Classification (Luminal A and B).
Clinicopathologic Variable Category Luminal A P Luminal B P
Negative for ANAPC13 (%)* Positive for ANAPC13 (%)* Negative for ANAPC13 (%)* Positive for ANAPC13 (%)*
Lymph node metastasis ≤3 17 (28.30) 43 (71.70) .01† 1 (25.00) 3 (75.00) >.999
>3 14 (56.00) 11 (44.00) 1 (33.30) 2 (66.70)
Nuclear grade 1 1 (100.00) 0 (0.00) NA 0 (0.00) 0 (0.00) NA
2 7 (35.00) 13 (65.00) 0 (0.00) 2 (100.00)
3 24 (41.40) 34 (58.60) 2 (50.00) 2 (50.00)
In situ lesion absent 18 (45.00) 22 (55.00) .76 1 (50.00) 1 (50.00) NA
present 7 (50.00) 7 (50.00) 0 (0.00) 0 (0.00)
SBR grade 1 7 (43.70) 9 (56.30) .22 0 (0.00) 1 (100.00) NA
2 21 (47.70) 23 (52.30) 2 (50.00) 2 (50.00)
3 4 (23.50) 13 (76.50) 0 (0.00) 1 (100.00)
Clinical stage I + II 19 (40.00) 29 (60.00) .85 2 (67.00) 1 (33.00) .52
III + IV 17 (38.00) 28 (62.00) 3 (33.00) 6 (67.00)
IDC indicates invasive ductal carcinoma; NA, not applicable; SBR grade, Scarff-Bloom-Richardson grade.
*Percentage of cases with complete information.
†P < .05.
Table W8. Genomic Alterations in ANAPC13.
Genomic Alteration mRNA Region Genotype Frequency n = 42 (%)
c.−704G>C 5′UTR Homozygous 27 (64.2%)
Heterozygous 10 (23.8%)
c.−702_700 del GGG 5′UTR Homozygous 36 (85.7%)
Heterozygous 0 (0.0%)
c.−700 del G 5′UTR Homozygous 1 (2.4%)
Heterozygous 0 (0.0%)
c−531 C>G 5′UTR Homozygous 1 (2.4%)
Heterozygous 0 (0.0%)
c−662C>T 5′UTR Homozygous 1 (2.4%)
Heterozygous 0 (0%)
c.*3C>T 3′UTR Homozygous 1 (2.4%)
Heterozygous 0 (0%)
c.*193G>A 3′UTR Homozygous 1 (2.4%)
Heterozygous 0 (0.0%)
UTR indicates untranslated region.
Table W7. Association between ANAPC13 Cytoplasmic Staining and Clinicopathologic Variables in IDC Cases Classified According to the Molecular Classification (HER2+, Basal-like,
and Unclassified).
Clinicopathologic
Variable
Category HER2+ P Basal-like P Unclassified P
Negative for
ANAPC13 (%)*
Positive for
ANAPC13 (%)*
Negative for
ANAPC13 (%)*
Positive for
ANAPC13 (%)*
Negative for
ANAPC13 (%)*
Positive for
ANAPC13 (%)*
Lymph node metastasis ≤3 6 (50.00) 6 (50.00) .31 3 (43.00) 4 (57.00) NA 2 (20.00) 8 (80.00) .06
>3 1 (16.70) 5 (83.30) 0 (0.00) 2 (100.00) 5 (71.00) 2 (29.00)
Nuclear grade 1 3 (50.00) 3 (50.00) NA 0 (0.00) 0 (0.00) NA 1 (50.00) 1 (50.00) .20
2 6 (46.20) 7 (53.80) 1 (50.00) 1 (50.00) 1 (33.00) 2 (67.00)
3 0 (0.00) 0 (0.00) 3 (33.00) 6 (67.00) 7 (47.00) 8 (53.00)
In situ lesion absent 6 (50.00) 6 (50.00) >.999 2 (67.00) 1 (33.00) >.999 4 (44.00) 5 (56.00) >.999
present 1 (50.00) 1 (50.00) 1 (50.00) 1 (50.00) 1 (50.00) 1 (50.00)
SBR grade 1 3 (75.00) 1 (25.00) .37 0 (0.00) 0 (0.00) NA 1 (25.00) 3 (75.00) .17
2 3 (37.5) 5 (62.50) 2 (29.00) 5 (71.00) 7 (64.00) 4 (36.00)
3 2 (33.00) 4 (66.70) 2 (50.00) 2 (50.00) 1 (20.00) 4 (80.00)
Clinical stage I + II 4 (44.00) 5 (56.00) >.999 1 (33.00) 2 (67.00) >.999 7 (70.00) 3 (30.00) .30
III + IV 3 (43.00) 4 (57.00) 3 (43.00) 4 (57.00) 2 (33.00) 4 (67.00)
IDC indicates invasive ductal carcinoma; NA, not applicable; SBR grade, Scarff-Bloom-Richardson grade.
*Percentage considering the number of cases with complete information.
Table W9. Analyses of ANAPC13 Expression in Molecular Subtypes of Invasive Ductal Carcinoma.
Molecular Subtype High Expression of
ANAPC13 (n%)
Low Expression of
ANAPC13 (n%)
P
Luminal A 6 (50.00) 6 (50.00) .36
Luminal B 3 (75.00) 1 (25.00)
HER2+ 2 (28.60) 5 (72.40)
Triple-negative 3 (30.00) 7 (70.00)
Figure W1.Mutation and deletion screening in ANAPC13. (A) Schematic representation of seven alterations found in ANAPC13 genomic
sequence. (B) Array CGH profile of a genomic segment at 3q22.2 from one sample of breast tumor. The figure depicts the location of the
three oligoprobes mapped within the sequence of the gene ANAPC13 (image extracted from the software Workbench DNA Analytics;
Agilent Technologies). The values of log ratios around 0 showed that the investigated ANAPC13 sequences had copy number equivalent
to the whole genome of this tumor, suggesting that no deletions were observed.
